Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Subscribe to see Siegfried Holding AG’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Siegfried Holding AG is a pharma, life sciences company headquartered in Zofingen, Switzerland, founded in 1873. It is publicly listed (SFZN) with a market capitalisation of $4B. Xcout tracks 14 named people at Siegfried Holding AG, including Marcel Imwinkelried (Chief Executive Officer and COO Drug Products ad interim).
8 more named people on record for Siegfried Holding AG, with roles, board committees and tenure — see the full roster →
A few of Siegfried Holding AG's closest competitors — see the full list of competitors and alternatives →
Operating globally, PolyPeptide Group AG functions as a prominent contract development and manufacturing organization (CDMO). The company specializes in producing both proprietary and generic GMP-certified peptides, which are supplied to pharmaceutical and biotechnology firms. These crucial components are integrated into approved pharmaceutical products, drugs in various stages of clinical development, and generic medications. PolyPeptide Group also handles the manufacturing of bespoke research-grade peptides and is engaged in the development of neoantigen peptides designed to advance personalized cancer therapies. Its services further encompass the production of peptides for commercially available peptide therapeutics, as well as the creation of peptide-based generics for both human and animal health sectors, alongside peptides for the cosmetics industry. Additionally, the company offers vital regulatory affairs assistance. Established in 1952, PolyPeptide Group AG maintains its corporate headquarters in Zug, Switzerland, and operates as a subsidiary of Draupnir Holding B.V.
ten23 health is a Switzerland-based pharmaceutical development and manufacturing company focused on complex drug products, including biologics and sterile injectable medicines. It serves biotechnology and pharmaceutical companies by providing formulation, process development, analytical services, and clinical or commercial manufacturing support.
Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia. The company’s chemicals and intermediates include amines, anilines, azaindoles, benzimidazoles, benzoic acid derivatives, benzyl compounds, boron building blocks, chiral compounds, cyclohexane derivatives, cyclopropyl building blocks, indazoles, indoles, N-heterocycles, nitrate esters, nitroaromatic compounds, O-heterocycles, phenols and anisoles, and pyridine building blocks. It also offers Dottisol, an isosorbide dimethyl ether for application as a solubility enhancer in cosmetic, pharma, and agro products, as well as a performance additive in various industries. In addition, the company is involved in recycling and waste treatment which includes the recycling, thermal recovery, and high-temperature incineration of waste streams, as well as wastewater treatment and purification activities. Further, it offers chemical custom manufacturing, nitrosamine risk assessment, and containment services; and performance chemicals, including aromatic and alicyclic diamines, bio-based organosilanes, and phlegmatized azides. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. Dottikon ES Holding AG is a subsidiary of EVOLMA Holding AG.
Aenova Group is a leading worldwide contract manufacturer for the pharmaceutical and healthcare industry, headquartered in Starnberg, Germany. The company provides comprehensive development, manufacturing, and technology services for pharmaceutical products.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd, a company established in 1973 and operating from its headquarters in Taizhou, China, specializes in the production and global supply of active pharmaceutical ingredients (APIs) and their chemical precursors. Its extensive product catalog includes APIs designed for a wide range of therapeutic applications, encompassing treatments for central nervous system disorders (such as anti-depressants and Parkinson's disease), various infectious ailments (including antiviral, general anti-infection, and specific respiratory anti-infection agents), diabetes management, non-steroidal drugs, oncological therapies, Hepatitis C, and cardiovascular conditions. Furthermore, beyond its pharmaceutical focus, the company also furnishes specialized asymmetric catalysts and crucial materials utilized in lithium-ion batteries.
KD Pharma Group operates as a contract development and manufacturing organization (CDMO) providing services and products for the pharmaceutical and nutraceutical industries. The company specializes in lipids, omega-3s, small molecules, custom synthesis, and finished dosage forms such as softgels and liquids. It serves pharmaceutical companies, nutritional supplement brands, and specialty chemical markets.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.